Sana Biotechnology, Inc. — Form 8-K Summary
Reporting date: June 6, 2024; filed June 7, 2024. The filing reports results of the company’s 2024 annual meeting of stockholders held June 6, 2024. Sana is a Delaware corporation headquartered in Seattle, Washington, and its common stock trades on Nasdaq under the symbol SANA.
Annual Meeting Results
- Class III director elections: Joshua H. Bilenker, M.D.; Richard Mulligan, Ph.D.; and Mary Agnes (Maggie) Wilderotter were each elected to three-year terms expiring at the 2027 annual meeting, or until their successors are elected and qualified.
- Auditor ratification: Stockholders ratified the appointment of Ernst & Young LLP as Sana’s independent registered public accounting firm for the fiscal year ending December 31, 2024.
| Director nominee | For | Withheld | Broker non-votes |
|---|---|---|---|
| Joshua H. Bilenker, M.D. | 148,997,261 | 16,148,638 | 13,427,015 |
| Richard Mulligan, Ph.D. | 149,561,266 | 14,901,700 | 14,109,948 |
| Mary Agnes (Maggie) Wilderotter | 144,161,860 | 20,256,138 | 14,154,916 |
| Auditor ratification | Votes |
|---|---|
| For | 178,501,678 |
| Against | 65,444 |
| Abstain | 5,792 |
Financial Metrics and Material Changes
This 8-K does not report revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other operating and financial metrics. It also does not disclose material changes versus a prior comparable period.
Outlook, Risks, and Unusual Items
The filing contains no management outlook, new risk disclosures, contingencies, or unusual financial items. Its principal effect is confirmation of the annual meeting’s director-election and auditor-ratification results.
Investor Verification Items
- Confirm the three elected Class III directors and their expected terms through the 2027 annual meeting.
- Review Sana’s proxy statement filed April 26, 2024 for proposal details and related governance information.
- Verify Ernst & Young LLP’s appointment for the fiscal year ending December 31, 2024.
- Consult Sana’s periodic reports for current financial condition, liquidity, operating performance, clinical developments, and risk factors, none of which are addressed in this filing.